Fractalkine Receptor CX3CR1 Is Expressed in Epithelial Ovarian Carcinoma Cells and Required for Motility and Adhesion to Peritoneal Mesothelial Cells

被引:54
作者
Kim, Mijung [1 ]
Rooper, Lisa [2 ]
Xie, Jia [1 ]
Kajdacsy-Balla, Andre A. [2 ]
Barbolina, Maria V. [1 ]
机构
[1] Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL 60612 USA
[2] Univ Illinois, Dept Pathol, Chicago, IL 60612 USA
关键词
CANCER CELLS; MICROENVIRONMENTAL REGULATION; MONOCLONAL-ANTIBODY; TUMOR-GROWTH; IN-VITRO; CHEMOKINE; METASTASIS; MIGRATION; MEDIATE; INVOLVEMENT;
D O I
10.1158/1541-7786.MCR-11-0256
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epithelial ovarian carcinoma (EOC) is a deadly disease, and little is known about the mechanisms underlying its metastatic progression. Using human specimens and established cell lines, we determined that the G-protein-coupled seven-transmembrane fractalkine receptor (CX(3)CR1) is expressed in primary and metastatic ovarian carcinoma cells. Ovarian carcinoma cells robustly migrated toward CX(3)CL1, a specific ligand of CX3CR1, in a CX(3)CR1-dependent manner. Silencing of CX3CR1 reduced migration toward human ovarian carcinoma ascites fluid by approximately 70%. Importantly, adhesion of ovarian carcinoma cells to human peritoneal mesothelial cells was dependent on CX(3)CL1/CX(3)CR1 signaling. In addition, CX3CL1 was able to induce cellular proliferation. Together, our data suggest that the fractalkine network may function as a major contributor to the progression of EOC, and further attention to its role in the metastasis of this deadly malignancy is warranted. Mol Cancer Res; 10(1); 11-24. (C) 2011 AACR.
引用
收藏
页码:11 / 24
页数:14
相关论文
共 62 条
[51]  
Scotton CJ, 2002, CANCER RES, V62, P5930
[52]   Fractalkine in the peritoneal fluid of women with endometriosis [J].
Shimoya, K ;
Zhang, Q ;
Temma-Asano, K ;
Hayashi, S ;
Kimura, T ;
Murata, Y .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2005, 91 (01) :36-41
[53]   CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells [J].
Shulby, SA ;
Dolloff, NG ;
Stearns, ME ;
Meucci, O ;
Fatatis, A .
CANCER RESEARCH, 2004, 64 (14) :4693-4698
[54]  
Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI [10.3322/caac.21654, 10.3322/caac.21387, 10.3322/caac.21669]
[55]  
Sood A, 1997, J Assoc Physicians India, V45, P283
[56]   β1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro [J].
Strobel, T ;
Cannistra, SA .
GYNECOLOGIC ONCOLOGY, 1999, 73 (03) :362-367
[57]   Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation [J].
Takaishi, Kiyomi ;
Komohara, Yoshihiro ;
Tashiro, Hironori ;
Ohtake, Hideyuki ;
Nakagawa, Takenobu ;
Katabuchi, Hidetaka ;
Takeya, Motohiro .
CANCER SCIENCE, 2010, 101 (10) :2128-2136
[58]   Management of recurrent epithelial ovarian carcinoma [J].
Vasey, PA .
AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2005, 45 (04) :269-277
[59]   Chemokines and their receptors: Drug targets in immunity and inflammation [J].
Viola, Antonella ;
Luster, Andrew D. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2008, 48 :171-197
[60]   Chemokines and their role in tumor growth and metastasis [J].
Wang, JM ;
Deng, XY ;
Gong, WH ;
Su, SB .
JOURNAL OF IMMUNOLOGICAL METHODS, 1998, 220 (1-2) :1-17